Pharma and healthcare News: Pharma and healthcare Latest News, Pharma and healthcare Today news, Pharma and healthcare Breaking News

Stock exchange trading dashboard showing Symbiotic Pharmalab shares listing flat at ₹988 on NSE and at a 1% discount of ₹978.20 on BSE against the issue price of ₹988.

Symbiotec Pharmalab lists flat at Rs 988 on NSE and 1% lower on BSE after Rs 1,757 crore IPO; check…

September 1, 2026 10:06 IST

Jefferies CRDMO stock picks including Sai Life Sciences and Divi's Laboratories

Jefferies rates 5 CRDMO stocks ‘Buy’ with up to 20% upside potential

Jefferies is turning bullish on India’s CRDMO space after a strong quarter. Sai Life Sciences and Divi’s Laboratories remain top…

Updated: August 27, 2026 10:40 IST

A financial graphic focusing on the Nifty Healthcare Index breakout, showing technical chart setups for Torrent Pharma, Apollo Hospitals, Divi's Labs, and Mankind Pharma supporting the move towards 17,600, against a backdrop of a strong bullish weekly candle.

Monday Watchlist: Will short-covering extend Nifty’s rally? Torrent Pharma, Apollo Hospitals in focus

Nifty’s short-covering rally may extend as Metal and Healthcare flash bullish setups; watch Torrent Pharma, Apollo and key levels Monday.

August 3, 2026 05:30 IST

Cipla vs Dr Reddy Q1 FY27 earnings and US pipeline comparison

Cipla Vs Dr. Reddy’s: Which pharma giant offers better risk-reward as spotlight shifts to US pipeline

Cipla and Dr. Reddy’s entered FY27 on different trajectories. While Cipla posted record quarterly revenue backed by respiratory growth, Dr.…

Updated: July 29, 2026 13:08 IST

Technical candlestick analysis chart showing Nifty Financial Services Index testing pattern support near 25,300 and Nifty Pharma Index approaching a crucial rising trendline support around 25,350.

Monday Watchlist: Smart Money vs Retail — Will Nifty bounce as pharma, financials test support?

Nifty eyes an expiry bounce as FIIs stay heavily short and pharma, financials test key supports; watch 25,300 breaks for…

July 27, 2026 05:30 IST

Trump's proposed generic drug tariffs and Indian pharma outlook by Bernstein

Why Trump’s tariff plan may more likely benefit Indian pharma than hurt? Bernstein explains

Bernstein says Trump’s proposed tariffs on generic medicines may create near-term uncertainty, but large Indian drugmakers remain well positioned for…

July 23, 2026 15:20 IST

A financial trading screen showing Dr. Reddy’s Laboratories' stock price declining 7% to a 52-week low on the NSE. The interface overlays key Q1FY27 financial metrics, including a 69% YoY drop in net profit, a ₹240 crore Semaglutide API inventory provision, and EBITDA margin contraction to 10%.

Dr Reddy’s slides to 52-week low: Brokerages slash price target on Semaglutide API, Middle East concerns

Dr Reddy’s hits a 52-week low after weak Q1 earnings, Semaglutide API issues and Middle East costs trigger target cuts;…

July 23, 2026 10:53 IST

A financial trading terminal displaying the Nifty Pharma Index drop alongside a visual timeline breakdown of Donald Trump's phased tariff policy on generic drug imports—showing 0% duty until August 2028, 100% in 2028–2029, and 200% from August 2029 onward.

Pharma stocks fall after Trump’s 200% tariff announcement for generic imports: Experts decode what it means

Track pharma stocks as Trump’s phased US tariff plan hits sentiment, though analysts say India’s cost edge may cushion generic…

July 22, 2026 10:36 IST

A clean, modern financial analytics visual depicting Motilal Oswal's initiation of coverage on Emcure Pharma with a 'Buy' rating. The interface displays a target price of ₹2,260 representing over 27% upside, alongside projected 3-year CAGR growth metrics: 14% revenue, 20% EBITDA, and 28% PAT over FY26-28.

Emcure Pharma: Motilal Oswal initiates coverage, sees 27% upside on multi-engine growth opportunity

Track Emcure Pharma as Motilal Oswal starts Buy with a ₹2,260 target, citing 27% upside and multi-engine growth across chronic,…

July 21, 2026 13:08 IST

A sleek, dark-mode financial trading interface tracking large-cap healthcare equities. The dashboard visualizes a major vertical volume bar indicating a massive surge from a 42 lakh average to 8 crore shares traded, positioned alongside a prominent 52-week high marker pointing to Rs 444.50.

Biocon share price hits fresh 52-week high, volumes exploded by 180x as block deal buzz sparks 8% rally

Biocon surged 8% to a 52-week high as block-deal buzz sent volumes up 180x despite a Q4 profit slump; track…

July 14, 2026 14:18 IST

Close-up of a modern corporate biotechnology research screen mapping out localized manufacturing compliance data. Interactive panels track the progress of three upcoming fresh validation batches alongside long-term strategic EPS forecasts pointing toward Rs 78 driven by the Abatacept opportunity.

Dr Reddy’s: JM Financial decodes the semaglutide supply delay and the hidden catalyst set to drive the stock higher

JM Financial keeps Dr Reddy’s at Buy despite semaglutide delay, seeing 23% upside and an FY28 Abatacept catalyst—track the stock.

July 10, 2026 14:29 IST

Jubilant Pharmova's Pantoprazole oral suspension receives USFDA tentative approval

Jubilant Pharmova gets tentative USFDA nod for Pantoprazole oral suspension

Jubilant Pharmova expects final approval from the USFDA for its Pantoprazole oral suspension after the patent expires in 2026. Read…

June 26, 2026 12:45 IST

Close-up of a modern corporate financial terminal comparing consensus estimates with Nomura’s forward projections showing a 13% earnings premium alongside a green stock ticker loop for DRREDDY.

Dr Reddy’s: Why Nomura sees 35% upside potential after strategic consumer health pivot

Nomura sees 35% upside for Dr Reddy’s as it pivots to branded consumer health; check if now is the time…

June 23, 2026 12:22 IST

Candlestick chart showing a Nifty Pharma index trendline breakout with MACD histogram indicators confirming momentum.

Monday Watchlist: Can Biocon and other pharma stocks spark a Nifty turnaround as FIIs cover shorts?

Watch Biocon and pharma stocks for a potential Nifty rebound as FIIs cover shorts—stay updated on key breakout levels!

June 22, 2026 05:30 IST

A professional dual-monitor setup displaying technical analysis candlestick charts, MACD indicators, and moving averages for the Nifty Pharma and Metal indices on a financial trading desk.

Monday Watchlist: Nifty volatility persists as pharma and metal indices flash short-term reversal signals

Monday watchlist today, June 01: Nifty volatility continues as pharma and metal indices signal short-term reversals; review your trading strategy…

June 1, 2026 05:30 IST

Stock market electronic display board screen showing green bullish trend tickers for major private banks alongside a dipping consumer goods sector chart.

Market Watchlist: FII long-buildup sets stage for Nifty breakout; Private Banks lead, FMCG lags

Monday watchlist, May 24: FIIs spark fresh optimism with Friday longs; Private Banks set for a rally—track the momentum and…

May 25, 2026 05:30 IST

Jefferies Q1 healthcare stocks Torrent Pharma Apollo Hospitals earnings preview

Bernstein initiates coverage on 6 Indian Pharma Stocks: With 3 ‘Outperforms’ and 2 ‘Underperforms’

Indian pharma may be entering a new era. Bernstein says the next winners may not come from vanilla generics but…

Updated: May 22, 2026 10:50 IST

An infographic comparing Nomura’s target prices for Dr. Reddy’s, Cipla, and Crompton Greaves, highlighting growth drivers like GLP-1 drug traction and ECD market expansion.

Cipla, Dr Reddy’s Lab, Crompton Greaves: Nomura’s top picks with 17% to 26% upside potential

Nomura sees up to 26% upside in Cipla, Dr Reddy’s Lab, and Crompton Greaves—discover why these stocks are top picks…

Updated: May 14, 2026 15:29 IST

Pharma and Healthcare

Related News

Trending Topics